Crovalimab
Monoclonal antibody
Type?
TargetParoxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), sickle cell disease
Clinical data
Routes of
administration		once every 4 week subcutaneous injections maintenance (following an initial iv loading dose)
ATC code
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Crovalimab is an C5 inhibiting monoclonal antibody under investigation by Roche/Genentech for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).[1][2][3][4][5]

Following an initial i.v. loading dose, crovalimab is administered once every 4 weeks as a subcutaneous injection by the patient themselves or by a caregiver.[1][2] Administration can also be done in the clinic if self-injection is not desired by the doctor or the patient.[1][2]

Crovalimab is the subject of five Phase III studies for PNH and atypical hemolytic uremic syndrome (aHUS). It is also being investigated for the treatment of sickle cell disease and other conditions.[6]

Clinical trials

Three Phase 3 clinical trials have evaluated crovalimab in both patients who were C5 inhibitor–naive and those switching to crovalimab from other C5 inhibitors.

COMMODORE 1 (NCT04432584), is a Phase III, randomized clinical trial comparing crovalimab vs eculizumab in PNH patients treated with C5 inhibitors.[4]

COMMODORE 2 (NCT04434092), is a Phase III, randomized trial comparing crovalimab vs eculizumab in people with PNH who are naive to C5 inhibitor treatment.[5]

COMMODORE 3 (NCT04654468) is a Phase III single-arm trial run in China, studying crovalimab in C5 inhibitor-naive patients with PNH.[2]

References

  1. 1 2 3 Kulasekararaj, Austin; He, Guangsheng; Munir, Talha; Pu, Jeffrey; Risitano, Antonio; Röth, Alexander; Sima, Camelia S.; Appius, Anita; Sostelly, Alexandre; Sreckovic, Sasha; Vignal, Charlotte; Nishimura, Jun-Ichi (5 November 2020). "Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors". Blood. 136 (Supplement 1): 34. doi:10.1182/blood-2020-136647. S2CID 234740758.
  2. 1 2 3 4 Liu, Hui; Xia, Linghui; Weng, Jianyu; Zhang, Fengkui; He, Chuan; Gao, Sujun; Jia, Jinsong; Chang, Alice C.; Lundberg, Pontus; Sima, Camelia S.; Shi, Jane; Xiao, Zhenyu; Zhang, Yuchen; Zhang, Zilu; Fu, Rong (15 November 2022). "Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)". Blood. 140 (Supplement 1): 714–716. doi:10.1182/blood-2022-162452. S2CID 254397884.
  3. ↑ Röth, Alexander; Nishimura, Jun-ichi; Nagy, Zsolt; Gaàl-Weisinger, Julia; Panse, Jens; Yoon, Sung-Soo; Egyed, Miklos; Ichikawa, Satoshi; Ito, Yoshikazu; Kim, Jin Seok; Ninomiya, Haruhiko; Schrezenmeier, Hubert; Sica, Simona; Usuki, Kensuke; Sicre de Fontbrune, Flore; Soret, Juliette; Sostelly, Alexandre; Higginson, James; Dieckmann, Andreas; Gentile, Brittany; Anzures-Cabrera, Judith; Shinomiya, Kenji; Jordan, Gregor; Biedzka-Sarek, Marta; Klughammer, Barbara; Jahreis, Angelika; Bucher, Christoph; Peffault de Latour, Régis (19 March 2020). "The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria". Blood. 135 (12): 912–920. doi:10.1182/blood.2019003399. PMC 7082616. PMID 31978221.
  4. 1 2 "PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)". European Hematology Association (EHA) 2023: Annual meeting abstracts. S183 – via EHA Library.
  5. 1 2 "THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS". European Hematology Association (EHA) 2023: Annual meeting abstracts. S181 – via EHA Library.
  6. ↑ "Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition". Genentech Press Release.{{cite news}}: CS1 maint: url-status (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.